Monika Monika

Monika Monika

Auto-generated profile, based on publicly available information

Monika Monika

Noida Institute of Engineering and Technology (Pharmacy Institute)

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Trends in Immunotherapy
Verified
Journal Article
Open access
PDF file
NSNeha Singh
Neha Singh
RMRUPA MAZUMDER
RUPA MAZUMDER
MMMonika Monika
Monika Monika
SSSakshi Sakshi
Sakshi Sakshi
FKFahad Khan
Fahad Khan
BKBIMLESH KUMAR
BIMLESH KUMAR
Conjunctivitis, also known as pink eye, is a conjunctival inflammation. It is brought on by bacteria, viruses, toxins, and allergies, including coronaviruses, the most frequent reason being allergic conjunctivitis (AC), which is brought on by exposure to pollutants like pollen, animal hair, or mold. The primary contributor to it is the linkage of immunoglobulin E caused by allergens and receptors on stimulated conjunctival mast cells. As a consequence, mast cells are degranulated, along with the release of histamine, cytokines, chemokines, and lipid mediators. The particular eye tissues impacted and the immune mechanism(s) (both local and systemic) that are involved all play a role in the clinical course, length, intensity, and co-morbidities. It frequently occurs in conjunction with allergic rhinitis, also known as allergic rhino-conjunctivitis and other allergy conditions. Atopic keratoconjunctivitis, giant papillary conjunctivitis, seasonal and perennial conjunctivitis, and vernal keratoconjunctivitis are the different types of allergic conjunctivitis. Ocular allergies are frequently misdiagnosed and undertreated, despite the emergence of innovative therapeutic strategies. This review focuses on several previously published studies to discuss the available therapeutic options for treating allergic conjunctivitis as well as the potential targets for the therapies. The association of conjunctivitis with COVID-19, along with recent patents and research, has also been explored.

27 December 2022 in Trends in Immunotherapy
Verified
Journal Article
Open access
PDF file
SSSakshi Sakshi
Sakshi Sakshi
RMRUPA MAZUMDER
RUPA MAZUMDER
MMMonika Monika
Monika Monika
NSNeha Singh
Neha Singh
BKBIMLESH KUMAR
BIMLESH KUMAR
Allergen-specific immunotherapy (AIT) is an allergen-specific treatment for people with IgE-related allergies. Allergen-specific immunotherapy (AIT) is used to treat allergic disorders when symptoms persist despite medication and allergen avoidance. The therapy is presumed effective if it reduces the use of medications, improves the quality of life even after discontinuation of treatment, as well as prevents the conversion of one type of allergy to the other and the development of new sensitization. The allergen-specific immunotherapeutic agents can be administered sublingually, subcutaneously, or through some other routes, such as intra-lymphatically and epicutaneously to induce allergen tolerance by modifying immune responses (innate and adaptive). The primary mechanism of AIT is the induction of functional regulatory cells, such as regulatory T cells, follicular T cells, B cells, dendritic cells, innate lymphoid cells, and natural killer cells, which results in the control of the functions of type 2 inflammatory cells. However, there are several downsides to AIT, including the contentious treatment period resulting in high cost, systemic allergic reactions, and the lack of a biomarker for forecasting treatment responders. Vaccine adjuvants, adjunctive therapies, and novel vaccine technologies are currently being researched to address the issues associated with AIT. This article focuses on defined molecular approaches for improving the potential of specific immunotherapy that use recombinant allergen derivatives, allergen-derived peptides, virus-coupled allergens, nanoparticles, and specific adjuvants.

1 February 2026 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
KJKm. Preeti Jaiswal
Km. Preeti Jaiswal
MOMonika
Monika
RMRupa Mazumder
Rupa Mazumder
AMAvijit Mazumder
Avijit Mazumder
Traditional treatment methods for the management of diabetes, such as oral hypoglycemic medications and insulin injections, include drawbacks like systemic adverse effects, inconsistent medication levels, and low compliance. To avoid difficulties, glycemic levels in diabetic patients, a long-term metabolic condition, must be precisely and consistently controlled. Smart therapeutic systems allow for precise, on-demand medication release in response to local physiological or environmental cues, such as glucose levels, pH, temperature, or enzyme activity. They provide a possible substitute for conventional diabetic therapies. As these systems only administer medications when and where needed, they reduce side effects while simultaneously increasing therapeutic efficacy and patient compliance. These systems are designed to respond to signals from external sources (such as light, ultrasound, or magnetic fields) or stimuli like temperature, pH, glucose levels, and enzymes. As they use glucose-sensitive substances like phenylboronic acid, glucose oxidase, or polymers to precisely release insulin in hyperglycemic circumstances, glucose-responsive delivery methods are essential for diabetes. This review discusses a stimuli-responsive drug delivery system designed for diabetes treatment, with a focus on the developments in biomaterials, nanotechnology, and engineering that improve its effectiveness and biocompatibility. Along with the possibility of combining a stimuli-responsive drug delivery system with wearable technology for continuous glucose monitoring and intelligent insulin delivery, issues, such as manufacturing complexity, stability, and patient safety, are also addressed. The stimuli-responsive drug delivery system has the potential to revolutionize diabetes management by bridging the gap between physiological needs and therapeutic delivery, providing better glucose control, fewer side effects, and an enhanced standard of living for patients.

24 August 2026 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RSRishikesh Singh
Rishikesh Singh
MOMonika
Monika
RMRUPA MAZUMDER
RUPA MAZUMDER
AMAvijit Mazumder
Avijit Mazumder
MSManish Singh
Manish Singh
GSGurvinder Singh
Gurvinder Singh
Inflammation-Responsive Drug Delivery System (IR-DDS) is proposed as a novel strategy for targeted therapy of the chronic inflammation-associated diseases: inflammatory bowel disease (IBD), rheumatoid arthritis (RA), and sepsis. These smart systems take advantage of the characteristic pathological microenvironment in inflamed tissues—such as acidic pH (5-6.5), high levels of reactive oxygen species (ROS), overexpressed enzymes, including matrix metalloproteinases (MMPs), and reductive conditions from glutathione (GSH)—for drug-specific accumulation at the site of action and on-demand release. By capitalizing on stimulus-induced behaviors, such as pH-activated protonation and swelling, ROS-stimulated bond scission in thio-ketals or boronic esters, enzyme-cleavable peptide linkers, or GSH-triggered disulfides, IR-DDS have overcome drawbacks of traditional delivery systems, including low bioavailability, off-target effects, and systemic toxicity. The review discusses a variety of carrier systems, such as polymeric nanoparticles (PLGA, chitosan), liposomes, micelles, hydrogels, dendrimers, and hybrid nanocomposites that offer inherent biocompatibility, controllable degradation, and multiple functionalities for sustained delivery. This includes the use of muscle, pH-sensitive hydrogels for periodontitis, oxidation-responsive polypropylene sulfide nanoparticles for anti-inflammatory drug release in rheumatoid arthritis models, and enzyme-triggered gelatin complexes used to target inflamed tissue in IBD, which are striking examples. A sulfasalazine-loaded transdermal patch is shown for chronic inflammation assessment, with increased efficacy in preclinical animal models, such as rat colitis and mouse arthritis after localized delivery. Despite encouraging preclinical findings in lowering cytokine levels, joint swelling, and inflammation markers, clinical translation is hindered by disease heterogeneity, scalability, biocompatibility issues, and manufacturing complexity. Future perspectives: AI-guided green multi-stimuli systems and therapeutic drug delivery, and diagnostic imaging (such as fluorescence, MRI) using multifunctional nanoparticle hybrids for personalized precision therapy will most likely revolutionize the management of chronic inflammation.

6 August 2025 in Health Leadership and Quality of Life
Verified
Journal Article
Open access
PDF file
VSVivek Saraswat
Vivek Saraswat
PPPradeepta Sekhar Patro
Pradeepta Sekhar Patro
SRSourav Rampal
Sourav Rampal
MSMadireddy Sirisha
Madireddy Sirisha
MSMukesh Sharma
Mukesh Sharma
MMMonika Monika
Monika Monika
The new coronavirus disease epidemic of 2019 (COVID-19) has spread worldwide. A quick solution to meet the urgent demand for effective treatment may be drug repurposing. To treat COVID-19, evaluated the clinical effectiveness of hydroxychloroquine and chloroquine. The individuals that received a modest COVID-19 score were randomized to obtain the control therapy or hydroxychloroquine 800 milligrams once daily on Day 7 and 250 milligrams for nine days, except the evaluated the clinical effectiveness of hydrochloride and chlorin equine. Compared to the control group (CtrlGrp) (Group 3), adverse reactions were observed more frequently in those taking chloroquine (Group 1) and hydroxychloroquine (Group 2). The time to clinical recovery (TTCR) was shortened in the Group 1 relation to the CtrlGrp. In the Group 2, there was a tendency toward lower TTCR. Chloroquine and Group 2 reached viral RNA negative substantially faster than the CtrlGrp. The typical instances to become RNA negative in the groups treated with chloroquine, hydroxychloroquine, and controls comprised two days, two weeks, and seven days, correspondingly. Both the length of hospitalization and the results of the lung computed tomography (CT) indicated improvements in the hydroxychloroquine and chloroquine pharmacologic categories. This research provides evidence that hydrochlorothiazide may be used to treat mild COVID-19, and it complements more excellent investigations.

30 September 2026 in Current Chemical Biology
Verified
Journal Article
Closed access
PDF file
SSShreyansh Singh
Shreyansh Singh
MOMonika
Monika
RMRUPA MAZUMDER
RUPA MAZUMDER
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Introduction: Anxiety disorders have neurochemical imbalances, structural changes in the brain, and dysfunctional neurotransmitter systems. The challenge in treating these disorders is the complexity of the Blood-Brain Barrier (BBB) and the ineffectiveness of traditional pharmacological methods, which may not provide accurate targeting of drugs and could be toxic. Methodology: The literature study was performed to identify relevant studies on Stimuli-Responsive Drug Delivery Systems (SRDDS) and their uses in the treatment of anxiety. The major databases, including PubMed, Scopus, Web of Science, and Google Scholar, were thoroughly studied. Results: SRDDS had great potential in improving bioavailability, achieving targeted release, and reducing systemic side effects in the treatment of anxiety disorders. Responsive systems to internal and external stimuli helped improve drug penetration through the BBB and prolonged the effects. Discussion: The incorporation of SRDDS in the treatment of anxiety fills a major gap in the conventional delivery of drugs by ensuring a controlled release at the desired site. Although the interdisciplinary approach of nanotechnology, materials science, and neurobiology has helped advance the field, concerns about cost, reproducibility, and safety remain. Conclusion: SRDDS offers a new approach to managing anxiety by allowing for targeted, controlled, and flexible delivery of anxiolytics through the BBB. While most existing evidence is still at the preclinical level, ongoing investigations, the incorporation of biomarkers, and improvements in scalable manufacturing techniques could help turn these systems into effective, customized treatments for anxiety disorders.